Hostname: page-component-77c89778f8-rkxrd Total loading time: 0 Render date: 2024-07-18T19:39:51.407Z Has data issue: false hasContentIssue false
  • English
  • Français

Myasthenia Gravis Associated with Diphenylhydantoin Therapy For Epilepsy

Published online by Cambridge University Press:  18 September 2015

Joel Brumlik  and
Robert S. Jacobs
Joel Brumlik*
Affiliation:
Departments of Neurology and Pharmacology and Therapeutics, Loyola University Medical Center, 2160 South First Avenue, Maywood, Illinois 60153
Robert S. Jacobs
Affiliation:
Departments of Neurology and Pharmacology and Therapeutics, Loyola University Medical Center, 2160 South First Avenue, Maywood, Illinois 60153
*
Neurology, Loyola University Medical Center, 2160 South First Avenue, Maywood, Illinois 60153, U.S.A
Rights & Permissions [Opens in a new window]

Summary

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

A young woman with epilepsy developed myasthenic symptoms while taking diphenylhydantoin. The clinical, electromyographic and pharmacologic findings were consistent with myasthenia gravis. Symptoms of myasthenia ceased on withdrawal of the drug, and recurred on readministration, with little apparent relationship to serum phenytoin levels. This unusual effect is discussed with reference to the known effects of diphenylhydantoin at the neuromyal junction.

Type
Research Article
Information
Canadian Journal of Neurological Sciences , Volume 1 , Issue 2 , May 1974 , pp. 127 - 129
Copyright
Copyright © Canadian Neurological Sciences Federation 1974

References

Booker, H.E., Chun, R.W.M., Sangnino, M. (1970). Myasthenia gravis syndrome associated with trimethadione. Journal American Medical Association, 212, 2260–2263.CrossRefGoogle ScholarPubMed
Hoefer, P.D., Aronar, H., Rowland, L.P. (1958). Myasthenia gravis and epilepsy. Archives of Neurology and Psychiatry, 80, 10–17.CrossRefGoogle ScholarPubMed
Lascelles, P.T., Kocen, R.S. and Reynolds, E.H. (1970). The distribution of plasma phenytoin levels in epileptic patients. Journal of Neurology, Neurosurgery and Psychiatry, 33, 501–505.CrossRefGoogle ScholarPubMed
Merritt, H.H. and Putnam, T.J. (1938). Sodium diphenylhydantoinate in the treatment of convulsive disorders. Journal American Medical Association, 111, 1068–1073.CrossRefGoogle Scholar
Norris, F.H., Cotella, J. and Mcfarlin, D. (1964). Effect of diphenylhydantoin on neuromuscular synapses. Neurology, 14, 869–876.CrossRefGoogle Scholar
Raines, A. and Standaert, F.G. (1966). Pre- and postjunctional effects of diphenylhydantoin at the cat soleus neuromuscular junction. Journal of Pharmacology Experimental Therapeutics, 153, 361–366.Google Scholar
Regli, F. and Guggenheim, P. (1965). Myasthenisches Syndrom als seltene Komplikation unter Hydantoinbehandlung. Nervenarzt, 36, 315–318.Google Scholar
Peterson, H. (1966). Association of trimethadione therapy and myasthenia gravis. New England Journal of Medicine, 274, 506–507.CrossRefGoogle ScholarPubMed
Sa, P.C. and Feldman, D.S. (1973). Motor nerve terminal and muscle membrane stabilization by diphenylhydantoin administration. Archives of Neurology, 28, 376–379.Google Scholar
Toivakka, E. and Hokkanen, E. (1969). A neurophysiological study of the subclinical derangement of the neuromuscular transmission in epileptics using diphenylhydantoin. Scandanavian Journal Clinical Laboratory Investigation, 23, Supp., 108–66.Google Scholar
Woodbury, D.M. (1955). Effect of diphenylhydantoin on electrolytes and radial sodium turnover in brain and other tissue of normal, hyponatremic and postictal rats. Journal of Pharmacology Experimental Therapeutics, 115, 74–95.Google Scholar